IOL Chemicals and Pharmaceuticals peers

Companies like IOL Chemicals and Pharmaceuticalslatest year

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

IOLCP₹180.62

IOL Chemicals and Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersMOREPENLABFDCINNOVACAPORCHPHARMASENORESSANOFIGUJTHEMRPGLIFEMcap ₹5,302 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
IOLCP
FY26
MOREPENLAB
FY26
FDC
FY26
INNOVACAP
FY26
Peer
Average
Valuation — at last close
P/E38.51×72.59×◆ 21.78×41.95×45.44× -15%
P/B2.95×5.52×◆ 2.47×5.55×4.51× -35%
EV/EBITDA19.45×55.60×◆ 16.20×25.96×32.59× -40%
Market Cap₹5,302 Cr₹6,881 Cr₹6,131 Cr₹6,007 Cr₹6,339 Cr -16%
Growth
Revenue CAGR 3Y1.51%◆ 8.40%6.77%—7.58% -80%
Revenue CAGR 5Y—8.73%◆ 10.24%—9.48%
Net Income CAGR 3Y-0.36%◆ 34.87%13.23%—24.05% -101%
Revenue YoY (latest Q)37.08%◆ 81.38%20.95%33.94%45.42% -18%
Net Income YoY (latest Q)89.80%◆ 117.48%72.92%42.27%77.56% +16%
Profitability
EBITDA Margin11.60%6.96%◆ 15.94%14.90%12.60% -8%
Net Income Margin5.94%5.25%◆ 12.96%8.78%9.00% -34%
Return on Common Equity7.90%7.90%11.81%◆ 14.03%11.25% -30%
Return on Capital Employed10.29%6.55%11.69%◆ 15.38%11.21% -8%
Return on Assets5.54%5.11%◆ 9.99%8.38%7.83% -29%
Credit & Quality
Total Debt/Equity0.07×0.16×◆ 0.00×0.32×0.16× -56%
Interest Coverage12.97×5.43×◆ 57.54×11.70×24.89× -48%
Scale — latest FY
Revenue / Total Income₹2,319 Cr₹1,806 Cr₹2,171 Cr₹1,630 Cr₹1,869 Cr +24%
Net Income₹138 Cr₹94.9 Cr₹281 Cr₹143 Cr₹173 Cr -21%
Total Assets₹2,587 Cr₹1,936 Cr₹2,919 Cr₹1,838 Cr₹2,231 Cr +16%
EPS₹4.69₹1.73₹17.29₹25.02₹14.68 -68%
Book Value per Share₹61.27₹22.75₹152.64₹188.99₹121.46 -50%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.